MEDPACE HOLDINGS INC (MEDP) Fundamental Analysis & Valuation

NASDAQ:MEDP • US58506Q1094

463.25 USD
-2.61 (-0.56%)
Last: Mar 5, 2026, 12:25 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This MEDP fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

7

Overall MEDP gets a fundamental rating of 7 out of 10. We evaluated MEDP against 57 industry peers in the Life Sciences Tools & Services industry. MEDP has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. MEDP is growing strongly while it is still valued neutral. This is a good combination! With these ratings, MEDP could be worth investigating further for growth and quality investing!.


Dividend Valuation Growth Profitability Health

9

1. MEDP Profitability Analysis

1.1 Basic Checks

  • In the past year MEDP was profitable.
  • MEDP had a positive operating cash flow in the past year.
  • Each year in the past 5 years MEDP has been profitable.
  • In the past 5 years MEDP always reported a positive cash flow from operatings.
MEDP Yearly Net Income VS EBIT VS OCF VS FCFMEDP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

1.2 Ratios

  • MEDP has a Return On Assets of 22.84%. This is amongst the best in the industry. MEDP outperforms 98.25% of its industry peers.
  • Looking at the Return On Equity, with a value of 98.27%, MEDP belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
  • MEDP has a better Return On Invested Capital (71.19%) than 100.00% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for MEDP is significantly above the industry average of 11.61%.
  • The 3 year average ROIC (49.20%) for MEDP is below the current ROIC(71.19%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 22.84%
ROE 98.27%
ROIC 71.19%
ROA(3y)19.71%
ROA(5y)17.64%
ROE(3y)65.94%
ROE(5y)56.06%
ROIC(3y)49.2%
ROIC(5y)40.37%
MEDP Yearly ROA, ROE, ROICMEDP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20 40 60 80

1.3 Margins

  • MEDP has a better Profit Margin (17.83%) than 89.47% of its industry peers.
  • In the last couple of years the Profit Margin of MEDP has grown nicely.
  • MEDP has a Operating Margin of 21.14%. This is amongst the best in the industry. MEDP outperforms 89.47% of its industry peers.
  • In the last couple of years the Operating Margin of MEDP has grown nicely.
  • With a Gross Margin value of 30.06%, MEDP is not doing good in the industry: 73.68% of the companies in the same industry are doing better.
  • In the last couple of years the Gross Margin of MEDP has remained more or less at the same level.
Industry RankSector Rank
OM 21.14%
PM (TTM) 17.83%
GM 30.06%
OM growth 3Y3.46%
OM growth 5Y3.23%
PM growth 3Y2.01%
PM growth 5Y2.64%
GM growth 3Y0.5%
GM growth 5Y-0.03%
MEDP Yearly Profit, Operating, Gross MarginsMEDP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10 20 30 40

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. MEDP Health Analysis

2.1 Basic Checks

  • MEDP has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
  • The number of shares outstanding for MEDP has been reduced compared to 1 year ago.
  • Compared to 5 years ago, MEDP has less shares outstanding
  • There is no outstanding debt for MEDP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
MEDP Yearly Shares OutstandingMEDP Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M
MEDP Yearly Total Debt VS Total AssetsMEDP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B 2B

2.2 Solvency

  • An Altman-Z score of 6.83 indicates that MEDP is not in any danger for bankruptcy at the moment.
  • The Altman-Z score of MEDP (6.83) is better than 92.98% of its industry peers.
  • There is no outstanding debt for MEDP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 6.83
ROIC/WACC6.6
WACC10.78%
MEDP Yearly LT Debt VS Equity VS FCFMEDP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M

2.3 Liquidity

  • A Current Ratio of 0.74 indicates that MEDP may have some problems paying its short term obligations.
  • The Current ratio of MEDP (0.74) is worse than 92.98% of its industry peers.
  • MEDP has a Quick Ratio of 0.74. This is a bad value and indicates that MEDP is not financially healthy enough and could expect problems in meeting its short term obligations.
  • MEDP has a worse Quick ratio (0.74) than 91.23% of its industry peers.
  • The current and quick ratio evaluation for MEDP is rather negative, while it does have excellent solvency and profitability. These ratios do not necessarly indicate liquidity issues and need to be evaluated against the specifics of the business.
Industry RankSector Rank
Current Ratio 0.74
Quick Ratio 0.74
MEDP Yearly Current Assets VS Current LiabilitesMEDP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

8

3. MEDP Growth Analysis

3.1 Past

  • MEDP shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 21.14%, which is quite impressive.
  • MEDP shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 31.30% yearly.
  • The Revenue has grown by 19.97% in the past year. This is quite good.
  • The Revenue has been growing by 22.27% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)21.14%
EPS 3Y27.86%
EPS 5Y31.3%
EPS Q2Q%27.25%
Revenue 1Y (TTM)19.97%
Revenue growth 3Y20.12%
Revenue growth 5Y22.27%
Sales Q2Q%32.03%

3.2 Future

  • MEDP is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 10.29% yearly.
  • Based on estimates for the next years, MEDP will show a quite strong growth in Revenue. The Revenue will grow by 10.47% on average per year.
EPS Next Y9.87%
EPS Next 2Y10.52%
EPS Next 3Y10.19%
EPS Next 5Y10.29%
Revenue Next Year11.71%
Revenue Next 2Y9.56%
Revenue Next 3Y9.5%
Revenue Next 5Y10.47%

3.3 Evolution

  • The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
MEDP Yearly Revenue VS EstimatesMEDP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 1B 2B 3B 4B 5B
MEDP Yearly EPS VS EstimatesMEDP Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 10 20 30

More info and screens

Find the best growth stocksShow best growing peers

5

4. MEDP Valuation Analysis

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 30.28 indicates a quite expensive valuation of MEDP.
  • Based on the Price/Earnings ratio, MEDP is valued a bit cheaper than the industry average as 61.40% of the companies are valued more expensively.
  • The average S&P500 Price/Earnings ratio is at 27.03. MEDP is around the same levels.
  • A Price/Forward Earnings ratio of 27.56 indicates a quite expensive valuation of MEDP.
  • 66.67% of the companies in the same industry are more expensive than MEDP, based on the Price/Forward Earnings ratio.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 25.11, MEDP is valued at the same level.
Industry RankSector Rank
PE 30.28
Fwd PE 27.56
MEDP Price Earnings VS Forward Price EarningsMEDP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, MEDP is valued a bit cheaper than 61.40% of the companies in the same industry.
  • 85.96% of the companies in the same industry are more expensive than MEDP, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 19.14
EV/EBITDA 22.42
MEDP Per share dataMEDP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 40 60 80

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates MEDP does not grow enough to justify the current Price/Earnings ratio.
  • MEDP has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)3.07
PEG (5Y)0.97
EPS Next 2Y10.52%
EPS Next 3Y10.19%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. MEDP Dividend Analysis

5.1 Amount

  • MEDP does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

MEDP Fundamentals: All Metrics, Ratios and Statistics

MEDPACE HOLDINGS INC

NASDAQ:MEDP (3/5/2026, 12:25:35 PM)

463.25

-2.61 (-0.56%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)02-09
Earnings (Next)04-20
Inst Owners87.1%
Inst Owner Change-2.2%
Ins Owners0.44%
Ins Owner Change-5.17%
Market Cap13.05B
Revenue(TTM)2.53B
Net Income(TTM)451.12M
Analysts52.22
Price Target497.46 (7.38%)
Short Float %5.69%
Short Ratio3.99
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)8.54%
Min EPS beat(2)7.52%
Max EPS beat(2)9.56%
EPS beat(4)4
Avg EPS beat(4)9.37%
Min EPS beat(4)2.57%
Max EPS beat(4)17.84%
EPS beat(8)8
Avg EPS beat(8)12.36%
EPS beat(12)11
Avg EPS beat(12)11.35%
EPS beat(16)15
Avg EPS beat(16)14.34%
Revenue beat(2)2
Avg Revenue beat(2)0.84%
Min Revenue beat(2)0.75%
Max Revenue beat(2)0.93%
Revenue beat(4)4
Avg Revenue beat(4)3.88%
Min Revenue beat(4)0.75%
Max Revenue beat(4)9.78%
Revenue beat(8)4
Avg Revenue beat(8)0.78%
Revenue beat(12)7
Avg Revenue beat(12)1.31%
Revenue beat(16)10
Avg Revenue beat(16)1.28%
PT rev (1m)-10.2%
PT rev (3m)-9.01%
EPS NQ rev (1m)1.41%
EPS NQ rev (3m)2.05%
EPS NY rev (1m)0%
EPS NY rev (3m)0.52%
Revenue NQ rev (1m)2.42%
Revenue NQ rev (3m)2.43%
Revenue NY rev (1m)-0.24%
Revenue NY rev (3m)-0.21%
Valuation
Industry RankSector Rank
PE 30.28
Fwd PE 27.56
P/S 5.16
P/FCF 19.14
P/OCF 18.3
P/B 28.43
P/tB N/A
EV/EBITDA 22.42
EPS(TTM)15.3
EY3.3%
EPS(NY)16.81
Fwd EY3.63%
FCF(TTM)24.21
FCFY5.23%
OCF(TTM)25.32
OCFY5.47%
SpS89.82
BVpS16.3
TBVpS-8.4
PEG (NY)3.07
PEG (5Y)0.97
Graham Number74.9
Profitability
Industry RankSector Rank
ROA 22.84%
ROE 98.27%
ROCE 84.68%
ROIC 71.19%
ROICexc 333.94%
ROICexgc N/A
OM 21.14%
PM (TTM) 17.83%
GM 30.06%
FCFM 26.95%
ROA(3y)19.71%
ROA(5y)17.64%
ROE(3y)65.94%
ROE(5y)56.06%
ROIC(3y)49.2%
ROIC(5y)40.37%
ROICexc(3y)169.04%
ROICexc(5y)114.84%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)58.52%
ROCE(5y)48.87%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3Y101.11%
ROICexc growth 5Y74.12%
OM growth 3Y3.46%
OM growth 5Y3.23%
PM growth 3Y2.01%
PM growth 5Y2.64%
GM growth 3Y0.5%
GM growth 5Y-0.03%
F-Score7
Asset Turnover1.28
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 111.49%
Cap/Sales 1.24%
Interest Coverage 250
Cash Conversion 126.67%
Profit Quality 151.15%
Current Ratio 0.74
Quick Ratio 0.74
Altman-Z 6.83
F-Score7
WACC10.78%
ROIC/WACC6.6
Cap/Depr(3y)125.21%
Cap/Depr(5y)134.9%
Cap/Sales(3y)1.64%
Cap/Sales(5y)1.98%
Profit Quality(3y)144.35%
Profit Quality(5y)141.17%
High Growth Momentum
Growth
EPS 1Y (TTM)21.14%
EPS 3Y27.86%
EPS 5Y31.3%
EPS Q2Q%27.25%
EPS Next Y9.87%
EPS Next 2Y10.52%
EPS Next 3Y10.19%
EPS Next 5Y10.29%
Revenue 1Y (TTM)19.97%
Revenue growth 3Y20.12%
Revenue growth 5Y22.27%
Sales Q2Q%32.03%
Revenue Next Year11.71%
Revenue Next 2Y9.56%
Revenue Next 3Y9.5%
Revenue Next 5Y10.47%
EBIT growth 1Y19.71%
EBIT growth 3Y24.28%
EBIT growth 5Y26.22%
EBIT Next Year16.28%
EBIT Next 3Y12.32%
EBIT Next 5Y12.46%
FCF growth 1Y19.15%
FCF growth 3Y24.75%
FCF growth 5Y24.56%
OCF growth 1Y17.15%
OCF growth 3Y22.49%
OCF growth 5Y22.49%

MEDPACE HOLDINGS INC / MEDP FAQ

What is the fundamental rating for MEDP stock?

ChartMill assigns a fundamental rating of 7 / 10 to MEDP.


Can you provide the valuation status for MEDPACE HOLDINGS INC?

ChartMill assigns a valuation rating of 5 / 10 to MEDPACE HOLDINGS INC (MEDP). This can be considered as Fairly Valued.


What is the profitability of MEDP stock?

MEDPACE HOLDINGS INC (MEDP) has a profitability rating of 9 / 10.


What are the PE and PB ratios of MEDPACE HOLDINGS INC (MEDP) stock?

The Price/Earnings (PE) ratio for MEDPACE HOLDINGS INC (MEDP) is 30.28 and the Price/Book (PB) ratio is 28.43.


How financially healthy is MEDPACE HOLDINGS INC?

The financial health rating of MEDPACE HOLDINGS INC (MEDP) is 8 / 10.